SG11201811291QA - Industrial process for the preparation of cariprazine - Google Patents

Industrial process for the preparation of cariprazine

Info

Publication number
SG11201811291QA
SG11201811291QA SG11201811291QA SG11201811291QA SG11201811291QA SG 11201811291Q A SG11201811291Q A SG 11201811291QA SG 11201811291Q A SG11201811291Q A SG 11201811291QA SG 11201811291Q A SG11201811291Q A SG 11201811291QA SG 11201811291Q A SG11201811291Q A SG 11201811291QA
Authority
SG
Singapore
Prior art keywords
international
trans
cariprazine
budapest
cyclohexyl
Prior art date
Application number
SG11201811291QA
Other languages
English (en)
Inventor
József Neu
Sándor Garadnay
Tamás Szabó
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of SG11201811291QA publication Critical patent/SG11201811291QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/48Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/26Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11201811291QA 2016-07-08 2017-07-07 Industrial process for the preparation of cariprazine SG11201811291QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUP1600420 2016-07-08
HU1700197A HU231173B1 (hu) 2016-07-08 2017-05-09 Ipari eljárás cariprazine előállítására
PCT/IB2017/054094 WO2018007986A1 (en) 2016-07-08 2017-07-07 Industrial process for the preparation of cariprazine

Publications (1)

Publication Number Publication Date
SG11201811291QA true SG11201811291QA (en) 2019-01-30

Family

ID=89992438

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811291QA SG11201811291QA (en) 2016-07-08 2017-07-07 Industrial process for the preparation of cariprazine

Country Status (22)

Country Link
EP (2) EP4043446A3 (zh)
JP (1) JP7065824B2 (zh)
CN (1) CN109476617B (zh)
AU (1) AU2017292177B2 (zh)
BR (1) BR112018077305A2 (zh)
CA (1) CA3030102A1 (zh)
DK (1) DK3481811T3 (zh)
EA (1) EA036312B1 (zh)
ES (1) ES2924995T3 (zh)
GE (1) GEP20217217B (zh)
HR (1) HRP20221037T1 (zh)
HU (2) HU231173B1 (zh)
IL (1) IL264074B (zh)
LT (1) LT3481811T (zh)
MX (2) MX2019000330A (zh)
PL (1) PL3481811T3 (zh)
PT (1) PT3481811T (zh)
RS (1) RS63480B1 (zh)
SG (1) SG11201811291QA (zh)
SI (1) SI3481811T1 (zh)
UA (1) UA123797C2 (zh)
WO (1) WO2018007986A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110240548A (zh) * 2018-03-09 2019-09-17 上虞京新药业有限公司 一种卡利拉嗪中间体的制备方法
CN110317182B (zh) * 2018-03-29 2021-10-15 上虞京新药业有限公司 一种卡利拉嗪的制备方法
CN108586389B (zh) * 2018-06-29 2020-06-12 成都福柯斯医药技术有限公司 一种合成卡利拉嗪的方法
CN111712486A (zh) * 2018-09-21 2020-09-25 上海诚妙医药科技有限公司 卡利拉嗪盐酸盐的新晶型及其制备方法及其用途
CN114539185A (zh) * 2020-11-24 2022-05-27 上海博志研新药物技术有限公司 一种卡利拉嗪及其中间体的制备方法
HUP2100108A1 (hu) 2021-03-12 2022-09-28 Richter Gedeon Nyrt Eljárás és berendezés gyógyászatilag alkalmazható piperazin származékok folyamatos áramú, áramlásos konszekutív redukálással történõ elõállítására
CN115806510B (zh) * 2023-02-03 2023-04-21 成都福柯斯医药技术有限公司 3-反式-4-(2-羟乙基)环己基-1,1-二甲基脲的合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010009912A1 (en) 1995-02-10 2001-07-26 Christos Tsaklakidis New derivatives of pyridil piperazine or pyridazinyl piperazyl, process for production thereof and medicaments containing these compounds
HU227543B1 (en) 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
HU227534B1 (en) 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
UY29161A1 (es) 2004-10-15 2006-04-28 Bayer Pharmaceuticals Corp Nuevos heterociclos
HU229858B1 (en) * 2008-12-17 2014-10-28 Richter Gedeon Nyrt Process for the preparation of trans 4-amino-cyclohexyl acetic acid ethyl ester hcl
HU230067B1 (hu) 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
US8912197B2 (en) * 2012-08-20 2014-12-16 Forest Laboratories Holdings Ltd. Crystalline form of carbamoyl-cyclohexane derivatives
HU231227B1 (hu) * 2012-11-29 2022-03-28 Richter Gedeon Nyrt. Transz-4-{2-[4-(2,3-diklórfenil)-piperazin-1-il]-etil}N,N-dimetilkarbamoil-ciklohexilamin skizofrénia negatív tüneteinek kezelésére
ITMI20131693A1 (it) 2013-10-14 2015-04-15 Chemo Res S L Derivati della 1,4-cicloesilammina e loro preparazione
CN105218484B (zh) * 2015-09-14 2018-02-23 安徽省逸欣铭医药科技有限公司 酒石酸卡利拉嗪及其制备方法和医药用途
CN105330616B (zh) * 2015-12-09 2017-09-26 苏州明锐医药科技有限公司 卡利拉嗪的制备方法

Also Published As

Publication number Publication date
EP4043446A2 (en) 2022-08-17
IL264074A (en) 2019-01-31
EP4043446A3 (en) 2023-01-18
AU2017292177B2 (en) 2021-07-29
IL264074B (en) 2021-10-31
JP2019527210A (ja) 2019-09-26
AU2017292177A1 (en) 2019-02-07
CN109476617B (zh) 2023-04-04
EP3481811B1 (en) 2022-05-25
MX2021012390A (es) 2022-07-18
HRP20221037T1 (hr) 2022-11-11
EA201990097A1 (ru) 2019-06-28
HUP1700197A2 (en) 2018-09-28
PT3481811T (pt) 2022-08-23
HUE059285T2 (hu) 2022-11-28
PL3481811T3 (pl) 2022-09-12
WO2018007986A1 (en) 2018-01-11
JP7065824B2 (ja) 2022-05-12
MX2019000330A (es) 2019-05-20
BR112018077305A2 (pt) 2019-04-02
RS63480B1 (sr) 2022-08-31
CN109476617A (zh) 2019-03-15
LT3481811T (lt) 2022-08-25
EP3481811A1 (en) 2019-05-15
DK3481811T3 (da) 2022-09-05
GEP20217217B (en) 2021-02-10
SI3481811T1 (sl) 2022-10-28
UA123797C2 (uk) 2021-06-02
EA036312B1 (ru) 2020-10-26
ES2924995T3 (es) 2022-10-13
CA3030102A1 (en) 2018-01-11
HU231173B1 (hu) 2021-06-28

Similar Documents

Publication Publication Date Title
SG11201811291QA (en) Industrial process for the preparation of cariprazine
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201909011PA (en) Niraparib compositions
SG11201809830WA (en) Selective reduction of cysteine-engineered antibodies
SG11201406888QA (en) Lysin-glutamic acid dipeptide derivatives
SG11201908650PA (en) Optimized antibody compositions for treatment of ocular disorders
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201408769QA (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
SG11201811671XA (en) Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201407115XA (en) Carboxylic acid compounds
SG11201806267QA (en) Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose
SG11201803627XA (en) N-substituted indole derivatives as pge2 receptor modulators
SG11201808686VA (en) Synthesis of indazoles
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201407546QA (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
SG11201900904PA (en) Methods for cross coupling
SG11201901558VA (en) Pth compounds with low peak-to-trough ratios
SG11201908097YA (en) Pyrimidine derivatives as pge2 receptor modulators
SG11201805387RA (en) Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
SG11201807540UA (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
SG11201811416VA (en) Crystalline solid forms of a bet inhibitor
SG11201806480UA (en) Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
SG11201805001UA (en) Method of treating influenza a